NASDAQ · TTRX
Healthcare · Biotechnology
$10.61
Down-$0.33 (-3.10%)
Updated Oct 27, 2026, 2:06 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · TTRX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
TTRX closed at $10.61 after 21 trading sessions, down 18.63% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $10.16 | $10.82 | $10.04 | $10.61 | 98.18K |
| Oct 23, 2026 | $10.59 | $10.79 | $10.091 | $10.28 | 87.05K |
| Oct 22, 2026 | $10.05 | $10.47 | $9.83 | $10.18 | 113.12K |
| Oct 21, 2026 | $10.61 | $10.715 | $10.14 | $10.15 | 60.58K |
| Oct 20, 2026 | $10.54 | $10.74 | $10.28 | $10.47 | 76.91K |
| Oct 19, 2026 | $10.72 | $10.87 | $10.60 | $10.74 | 29.91K |
| Oct 16, 2026 | $11.49 | $11.49 | $10.39 | $10.57 | 105.63K |
| Oct 15, 2026 | $10.85 | $11.885 | $10.85 | $11.59 | 80.34K |
| Oct 14, 2026 | $10.42 | $11.44 | $10.42 | $11.11 | 53.37K |
| Oct 13, 2026 | $11.12 | $11.398 | $10.26 | $10.60 | 117.45K |
| Oct 12, 2026 | $11.72 | $11.985 | $11.03 | $11.11 | 45.98K |
| Oct 9, 2026 | $11.34 | $12.00 | $11.30 | $12.00 | 109.83K |
| Oct 8, 2026 | $11.94 | $12.00 | $11.24 | $11.39 | 110.13K |
| Oct 7, 2026 | $11.58 | $13.05 | $11.31 | $12.10 | 176.32K |
| Oct 6, 2026 | $12.35 | $12.42 | $11.57 | $11.64 | 74.85K |
| Oct 5, 2026 | $13.18 | $13.18 | $12.00 | $12.36 | 111.34K |
| Oct 2, 2026 | $13.35 | $13.48 | $12.17 | $13.33 | 136.3K |
| Oct 1, 2026 | $14.25 | $14.25 | $13.015 | $13.31 | 122.09K |
| Sep 30, 2026 | $13.41 | $14.63 | $13.02 | $14.39 | 88.72K |
| Sep 29, 2026 | $13.04 | $13.89 | $12.85 | $13.41 | 79.53K |
| Sep 28, 2026 | $12.29 | $13.125 | $12.285 | $13.04 | 76.73K |
The latest Smart Investors Daily articles mentioning TTRX.
Company
Market Activity
Research & News
TTRX research
Company profile and research snapshot.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 23, 2026 | WBB Securities | Hold | — |
| Sep 24, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| Sep 14, 2026 | WBB Securities | Sell | — |
| Mar 24, 2026 | D. Boral Capital | Buy | — |
| Jan 20, 2026 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 21, 2026
WESTLAKE VILLAGE, Calif., October 21, 2026--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead, will join in a U.S. Bancorp | BTIG virtual fireside chat as follows:
Yahoo · Oct 21, 2026
Dr. Robert Redfield and Dr. Stephen Hahn came aboard Turn Therapeutics this year to help the clinical-stage company develop a platform that could one day change how vaccines are delivered.
Benzinga · Sep 24, 2026
Analysts initiated coverage: ARES Overweight, $150; MGEE Neutral, $76; TTRX Buy, $24; QNCX Buy, $70; EFSC Buy, $70.
Benzinga · Sep 24, 2026
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Turn Therapeutics (NASDAQ:TTRX) with a Buy rating and announces Price Target of $24.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TTRX.
